4. Apply emerging therapies and novel treatment strategies for patients with hematologic malignancies and evaluate the practical utility of novel agents based on data from recent clinical studies to improve outcomes (knowledge, competence, performance, patient outcomes).

5. Differentiate the evolving therapeutic strategies for first-line, second-line, third-line, and salvage treatment of hematologic malignancies and apply these strategies into practice (knowledge, competence, performance).

Target Audience

This program is directed towards Physicians, RNs, PAs, PharmDs, Fellows and Students interested in Hematology Oncology, Medical Oncology and Internal Medicine.

Educational Methods

Lectures, Case Studies, Panel Discussions, Poster Session, Poster Presentations, Interactive Small Groups, Question-and-Answer Sessions

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and the Society of Hematologic Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.